Skip to main content
CDT logo

CDT Equity Inc. (CDT) Stock Price & Analysis

CDT Equity Inc. (CDT) — MoonshotScore 43/100 (Weak band), calculated Oct 5, 2026. Price $0.99 (-20.80%), as of the Oct 2, 2026 trading session.

Educational signal · not a buy or sell recommendation · How to read this

$0.99 −$0.26 (-20.80%)

CDT Equity Inc. · CDT

CDT Equity Inc. is a data-driven biopharmaceutical company focused on identifying, enhancing, and monetizing therapeutic assets.

Price as of Oct 2, 2026

Key Statistics

43 of 100

MoonshotScore v2 · CDT Equity (CDT)

Weak
Business Quality Average (56)
Financial Safety Fragile (16)
Valuation Cheap (83)
Growth Durability Fading (22)
Momentum Falling (7)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Cheap, but a fragile balance sheet and stalling growth, and the price trend has turned against it. Business Quality: Average; Financial Safety: Fragile; Valuation: Cheap; Growth Durability: Fading; Momentum: Falling.

  • quarterly revenue $750M (Q2 FY2026, quarter ended Jun 2026)
  • Altman Z 1.44 · Piotroski F 7
  • ROE 2.6% · ROA 0.5% · current ratio 2.09

Holding back: balance-sheet strain, soft growth, weak price trend

Helping: an attractive price

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for CDT (29 recorded, newest six shown)
RecordedScoreBand
43Weak
43Weak
43Weak
43Weak
43Weak
43Weak

The score was 43 in the stored Oct 4, 2026 snapshot and remains 43 in the current publication computed Oct 5, 2026 (0); the largest pillar moves were Growth Durability +1 and Momentum -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged. This current publication is not yet represented in the immutable snapshot archive.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.99
Change on the day-20.80%
52-week range$1.31 – $44450.00
Price / earnings (trailing)0.00
Shares traded on the day1.03M

Price & events

Other perspectives

Council score for CDT Equity (CDT): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

9-Factor Breakdown

Revenue Growth Neutral
Gross Margin Weak
Operating Leverage Neutral
Cash Runway Neutral
R&D Intensity Neutral
Insider Activity Moderate
Trading Liquidity Neutral
Price Momentum Negative
News Sentiment Neutral

Legends Council

3 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Unfavorable read

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Negative
Margin of Safety Undervalued
Profit Margin Neutral
Revenue Growth Weak
Debt/Equity Weak
ROE Weak
Gross Margin Neutral

Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 11, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Oct 5, 2026, except a card that shows its own read date.

Watch the CDT film — every key number, told as a short cinematic story

~2 min · open the film

1 · What is it?

What is CDT Equity (CDT), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. CDT Equity Inc. (CDT) is the company analyzed here. It employs 4 people and is led by Jamie Bligh. In Q2 FY2026 it reported revenue of $750M and net income of $69M.

2 · Latest results

What do the latest results show for CDT Equity (CDT)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $750M.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$750M$69M$1.74 (diluted)
Q1 FY2026$696M$51M$129.53 (diluted)
Q4 FY2025$0-$21M-$23.14 (diluted)
Q3 FY2025$0-$7M-$32.90 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for CDT Equity (CDT)?

Short answer

The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is balance-sheet strain, soft growth, weak price trend. The distress and quality screens read Altman Z 1.44 · Piotroski F 7. Trailing ratios: ROE 2.6% · ROA 0.5% · current ratio 2.09.

5 · Score methodology

How is CDT Equity scored?

Short answer · as of

A same-model peer rank is unavailable in the current peer set. The MoonshotScore combines business quality, financial safety, valuation, growth durability and momentum; open “Why this rating?” for the method and drivers.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
ImmuCell Corporation (ICCC) Same industry, near in market value$9.75 Oct 2, 2026$88.2M— Model unavailable
Rallybio Corporation (RLYB) Same industry, near in market value$17.08 Oct 2, 2026$90.6M— Model unavailable
Alopexx, Inc. (ALPX) Same industry, near in market value$9.96 Oct 2, 2026$119M— Model unavailable
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$4.49 Oct 2, 2026$184M— Model unavailable
AN2 Therapeutics, Inc. (ANTX) Same industry, near in market value$5.71 Oct 2, 2026$206M— Model unavailable
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$2.71 Oct 2, 2026$218M— Model unavailable
Niagen Bioscience Inc (NAGE) Same industry, near in market value$2.79 Oct 2, 2026$222M— Model unavailable
Q32 Bio Inc. (QTTB) Same industry, near in market value$8.23 Oct 2, 2026$245M— Model unavailable
CorMedix Inc. (CRMD) Same industry, near in market value$7.19 Oct 2, 2026$564M— Model unavailable
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.99 Oct 2, 2026$591M— Model unavailable
Climb Bio, Inc. (CLYM) Same industry, near in market value$10.94 Oct 2, 2026$626M— Model unavailable
MiMedx Group, Inc. (MDXG) Same industry, near in market value$4.59 Oct 2, 2026$669M— Model unavailable

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Insider activity

Form 4 records via FMP · Available records within the last 180 days, newest dated Aug 28, 2026 (coverage not recorded)

Transactions
9
Identified insiders
2
Purchases
0
Sales
5
Other transactions
4

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

What Investors Ask About CDT Equity (CDT)

These answers are editorial: 1 of these 9 answers is drawn from the CDT research dossier (written Jun 15, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for CDT?

CDT carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is CDT a good stock to buy?

Stock Expert AI does not rate CDT buy, sell or hold. CDT Equity Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CDT stock price today?

The last price recorded on this page for CDT Equity Inc. (CDT) is $0.99, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

How does CDT Equity Inc.'s data-driven approach differentiate it in the biopharmaceutical sector?

CDT Equity Inc. emphasizes a data-driven approach to differentiate itself in the highly competitive biopharmaceutical sector. This methodology is central to its strategy of identifying, enhancing, and monetizing therapeutic assets.

What are the key factors to evaluate for CDT?

CDT Equity Inc. (CDT) holds a MoonshotScore in the low range. P/E: 0.00x. Leveraging Data-Driven Approach for Asset Identification: The company's self-description as "data-driven" suggests a core competency in efficiently identifying and enhancing therapeutic assets. Not financial advice.

How frequently does CDT data refresh on this page?

CDT's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CDT's recent stock price performance?

CDT Equity Inc. (CDT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified biopharmaceutical pipeline addressing multiple therapeutic areas (autoimmune, diabetes, infertility). See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CDT overvalued or undervalued right now?

CDT Equity Inc. (CDT) trades at 0.00x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research CDT before investing?

Before investing in CDT Equity Inc. (CDT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources — records for every figure on this page (16 figures)

The 16 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.

"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.

FMP — 9 facts from Financial Modeling Prep endpoint families

FMP facts used on this page
Fact IDFactValue as shownAs ofTierSource
px.lastLatest provided price$0.99FMPFinancial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T06:34:22.479Z.
px.changeChange on the day-20.80%FMPFinancial Modeling Prep (FMP) · quote
px.change_absChange on the day, in dollars−$0.26FMPFinancial Modeling Prep (FMP) · quote
fin.q_revenueRevenue, Q2 FY2026$750MFMPFinancial Modeling Prep (FMP) · income statement (quarterly)
px.pePrice / earnings (trailing)0.00FMPFinancial Modeling Prep (FMP) · quote
px.volumeShares traded on the day1.03MFMPFinancial Modeling Prep (FMP) · quote
fin.q_incomeNet income, Q2 FY2026$69MFMPFinancial Modeling Prep (FMP) · income statement (quarterly)
fin.q_tableQuarterly income statement4 quarters through Q2 FY2026FMPFinancial Modeling Prep (FMP) · income statement (quarterly), as filed
own.insidersInsider transactions via FMP9 transactions · 0 purchases, 5 sales, 4 other transactions · 2 identified insiders · available records within the last 180 days, newest dated Aug 28, 2026 (coverage not recorded)FMPFinancial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

UNRECORDED — 5 facts from stored observations whose source was not recorded

UNRECORDED facts used on this page
Fact IDFactValue as shownAs ofTierSource
fin.scoresDistress and quality screensAltman Z 1.44 · Piotroski F 7UNRECORDEDStored financial-scores observation — Captured 2026-10-04 · Expired observation
fin.ratiosReturn and yield ratios (trailing twelve months)ROE 2.6% · ROA 0.5% · current ratio 2.09—UNRECORDEDStored key metrics — Date unknown
px.range5252-week range$1.31 – $44450.00UNRECORDEDStored company-profile observation — Captured 2026-10-01
id.employeesEmployees4UNRECORDEDStored company-profile observation — Captured 2026-10-01
id.ceoChief executiveJamie BlighUNRECORDEDStored company-profile observation — Captured 2026-10-01

OURS — 2 facts from Stock Expert AI's own score and rank

OURS facts used on this page
Fact IDFactValue as shownAs ofTierSource
ours.moonshotMoonshotScore v243 of 100 · Weak · pillars 56 / 16 / 83 / 22 / 7OURSStock Expert AI MoonshotScore v2 engine
ours.moonshot_changeMoonshotScore movement43 (stored snapshot Oct 4, 2026) → 43 (current publication computed Oct 5, 2026) (0)OURSStock Expert AI current score publication and immutable score snapshots — The current score publication is not yet represented in the immutable snapshot archive.
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.